CliffBio
small molecule

NEVIRAPINE

NEVIRAPINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEVIRAPINE
Active ingredientNEVIRAPINE
Strength400MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NEVIRAPINE patent cliff — loss of exclusivity — | CliffBio